Skip to main content

Table 1 Inclusion and exclusion criteria by cohort

From: Novel approaches to the prediction, diagnosis and treatment of cardiac late effects in survivors of childhood cancer: a multi-centre observational study

  Inclusion criteria Exclusion criteria
Acute Cohort 1. Aged <18 years at time of cancer diagnosis;
2. Diagnosed with a new malignancy;
3. Cancer treatment plan will require therapy with ≥1 dose of an anthracycline chemotherapy
4. Pre-anthracycline; echocardiograms to occur at the recruiting site;
5. Normal cardiac function prior to the initiation of anthracycline therapy (LVEF >55%).
1. Patients with significant congenital heart defects;
2. Patients who were previously treated with anthracycline chemotherapy or radiation to the chest.
Survivor Cohort 1. Aged <18 years at time of cancer diagnosis;
2. Previously diagnosed with cancer and currently in remission;
3. Patients whose prior treatment plan included therapy with ≥1 dose of anthracycline chemotherapy;
4. Patients who completed their final dose of anthracycline ≥3 years ago;
5. Patients who completed their final dose of a chemotherapy agent other than anthracycline ≥1 year ago;
6. Routinely followed at the recruiting site approximately every 12 months.
1. Prior allogeneic stem cell transplant;
2. Patients with significant congenital heart defects;
3. CMR: general contraindications for a contrast enhanced CMR, and patients who require anaesthesia for MRI (typically <6 years of age) will be excluded.